No connection

Search Results

GELS vs TNON

GELS
Gelteq Limited
BEARISH
Price
$0.77
Market Cap
$8.2M
Sector
Healthcare
AI Confidence
95%
TNON
Tenon Medical, Inc.
BEARISH
Price
$0.80
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
GELS
--
TNON
--
Forward P/E
GELS
--
TNON
-1.28
P/B Ratio
GELS
0.7
TNON
4.41
P/S Ratio
GELS
19.92
TNON
2.29
EV/EBITDA
GELS
-3.15
TNON
-0.72

Profitability

Gross Margin
GELS
72.07%
TNON
59.79%
Operating Margin
GELS
-2969.43%
TNON
-193.52%
Profit Margin
GELS
0.0%
TNON
0.0%
ROE
GELS
-42.99%
TNON
-228.06%
ROA
GELS
-15.0%
TNON
-72.88%

Growth

Revenue Growth
GELS
59.4%
TNON
92.3%
Earnings Growth
GELS
--
TNON
--

Financial Health

Debt/Equity
GELS
0.27
TNON
0.03
Current Ratio
GELS
0.27
TNON
2.11
Quick Ratio
GELS
0.14
TNON
1.7

Dividends

Dividend Yield
GELS
--
TNON
--
Payout Ratio
GELS
0.0%
TNON
0.0%

AI Verdict

GELS BEARISH

GELS exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis. While the company shows strong top-line revenue growth (59.40%) and healthy gross margins (72.07%), these are completely offset by a catastrophic operating margin of -2969.43%. With a current ratio of 0.27 and a quick ratio of 0.14, the company lacks the liquidity to meet its short-term obligations. Despite trading below book value (P/B 0.70), the fundamental instability and long-term price decay make this a high-risk speculative asset.

Strengths
Strong Gross Margin of 72.07%
Robust YoY Revenue Growth of 59.40%
Low Debt-to-Equity ratio (0.27)
Risks
Severe liquidity shortage (Current Ratio 0.27)
Extreme operational inefficiency (Operating Margin -2969.43%)
Weak Piotroski F-Score (3/9) indicating deteriorating fundamentals
TNON BEARISH

TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.

Strengths
Strong YoY revenue growth of 92.30%
High gross margin of 59.79% indicating product value
Very low leverage with a Debt/Equity ratio of 0.03
Risks
Critical financial health as evidenced by Piotroski F-Score of 1/9
Severe operational losses with an operating margin of -193.52%
Extreme equity erosion indicated by ROE of -228.06%

Compare Another Pair

GELS vs TNON: Head-to-Head Comparison

This page compares Gelteq Limited (GELS) and Tenon Medical, Inc. (TNON) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile